Adam Haydt

Explore one of biopharma’s most pressing EHS challenges: managing hazardous, biological, and wastewater streams responsibly across emerging modalities. From ADCs and gene therapies to PFAS and radiopharmaceuticals, participants will examine real-world regulatory gaps, vendor partnerships, and accountability issues that extend beyond the lab. Delegates will walk away with strategies for aligning government oversight, contractor competence, and internal sustainability goals to create a resilient, transparent waste management culture.

Key Questions to Be Addressed:

• How can sites maintain oversight once hazardous or biological waste leaves the facility, especially in regions with weak regulations or limited contractor competence?
• How should hybrid compounds like ADCs be classified and disposed of responsibly to balance chemical and biological risks?
• What systems or partnerships can improve coordination and traceability across regulators, vendors, and contractors?
• How can sites manage biologics- or PFAS-contaminated wastewater to meet discharge limits and prevent downstream contamination?
• How can data sharing and AI tools optimise costly waste and incineration decisions while ensuring compliance and sustainability?